ResMed (ASX:RMD) share price tumbles on broker downgrade

This leading broker believes the ResMed share price has peaked…

| More on:
concerned and worried man looking at computer and monitoring falling share price

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc (ASX: RMD) share price is out of form on Tuesday.

In afternoon trade, the sleep treatment focused medical device company's shares are down 2.5% to $31.82.

Despite this decline, the ResMed share price is still up over 17% since the start of the month.

Why is the ResMed share price dropping?

Today's decline appears to have been driven by a combination of broad market weakness and a broker note out of Citi.

In respect to the latter, this morning analysts at Citi downgraded the company's shares to a neutral rating with an improved price target of $32.50.

This was broadly in line with the ResMed share price prior to today's decline.

Why did Citi downgrade its shares?

According to the note, the broker made the move on valuation grounds after a strong gain by the ResMed share price this month.

It notes that this has been driven by news that rival Philips has recalled its DreamStation CPAP devices. And while the broker has upgraded its earnings estimates to reflect its belief that this development could be a short term boost to ResMed's sales, it feels this is now reflected in its shares.

Citi commented: "The recall of Philips' DreamStation CPAP devices creates an opportunity for RMD to fill the void in the short term and potentially make long-term market share gains. Philips is unlikely to be able to supply new patients until Jan 2022 as it ramps up production of its DreamStation 2 – new patients account for ~80% of Philips' CPAP devices sales."

"We upgrade FY22-23e EPS by 5%/10%, increase our TP to $32.50 (from $28.50) but downgrade to Neutral as the share price now reflects our base-case scenario. We assume RMD can increase its CPAP devices and masks manufacturing capacity by 20% and that Philips won't re-enter the new patient market for 12 months – these two variables are the main unknowns. RMD has not made any comments on the situation and will report FY21 in August," it concluded.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

A man slumps crankily over his morning coffee as it pours with rain outside.
Broker Notes

Guess which popular ASX 200 stock Bell Potter just downgraded

Let's see what the broker is saying on this blue chip.

Read more »

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Broker Notes

Leading brokers name 3 ASX shares to buy today

Here's why brokers believe that now could be the time to snap up these shares.

Read more »

Miner standing in a mine site with his arms crossed.
Broker Notes

Up 41% in 2025, does Macquarie think Lynas Rare Earths shares have peaked?

The company is up nearly 400% in 5 years.

Read more »

Three miners looking at a tablet.
Broker Notes

Macquarie tips 28% upside for this ASX All Ords mining stock

Let's see why the broker is bullish on this beaten down miner.

Read more »

a man looks down at his phone with a look of happy surprise on his face as though he is thrilled with good news.
Broker Notes

5 ASX 200 shares for smart investors to buy now

Brokers think these shares are smart buys. Let's find out what they are.

Read more »

Woman on a tablet waiting in for her flight in an airport and looking through a window.
Travel Shares

Up nearly 70% in a year, does JP Morgan think Qantas shares can go higher?

Qantas shares have been a home run for investors over both the short and long term.

Read more »

a man in a green and gold Australian athletic kit roars ecstatically with a wide open mouth while his hands are clenched and raised as a shower of gold confetti falls in the sky around him.
Broker Notes

5 Australian shares to buy with $5,000

Brokers are urging investors to snap up these shares right now.

Read more »

Broker Notes

Broker warns regulated electricity could threaten AGL shares 

What could the government review mean for utility stocks?

Read more »